Dr. Sutera opened his talk by outlining that he would divide his presentation into three parts: first, defining MMAI; second, discussing its application in oligometastatic prostate cancer; and third, ...

The study aims to accrue up to 41 patients at MD Anderson Cancer Center and partner sites. The study started enrolling in October 2024, and enrollment is ongoing with a primary completion estimate of ...

The U54 ROBIN consortium is a first-of-its-kind effort to study the biological effects of radiation before, during, and after treatment, using small study cohorts for detailed molecular ...

Next, Dr. Mouw addressed the secondary analysis of the RAVES trial, which compared adjuvant and early salvage radiotherapy in the post-prostatectomy setting. This pre-planned secondary analysis of ...

The 2025 ASTRO annual meeting featured a metastatic prostate cancer session and a discussant presentation by Dr. Comron ...

Enrollment was between October 2019 and December 2023, during which time 41 patients were assessed for eligibility and 32 patients were enrolled. The median age was 74.0 years (range: 61.0-82.0), the ...

The 2025 ASTRO annual meeting featured a clinical trials session and a presentation by Dr. Amar Kishan discussing the primary ...

Dr. Jani highlighted the EMPIRE-1 trial, which evaluated the role of 18F-fluciclovine PET in guiding post-prostatectomy ...

The 67 th American Society for Radiation Oncology (ASTRO) annual meeting held in San Francisco., between September 28 and September 30 was host to the Session16 - GU 4: Quality of Life Outcomes after ...

The co-primary endpoints were safety and efficacy: efficacy defined as ≥25% reduction in rectal rV70 in >75% of balloon ...

Dr. Yu began by highlighting that moderately hypofractionated IMRT (MH-IMRT) has been the standard of care for prostate cancer since RTOG 0415 and other landmark studies. 1 At the time this trial was ...

The 2025 ASTRO annual meeting featured a prostate cancer radiation toxicity session and a presentation by Dr. Young Suk Kwon discussing an EPIC-26 longitudinal analyses of prostatic urethral lift ...